Share on StockTwits

Arrowhead Research Corp (NASDAQ:ARWR) Director Charles Mckenney sold 22,000 shares of Arrowhead Research Corp stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $14.32, for a total transaction of $315,040.00. Following the completion of the transaction, the director now directly owns 17,220 shares of the company’s stock, valued at approximately $246,590. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Arrowhead Research Corp (NASDAQ:ARWR) traded up 3.04% during mid-day trading on Tuesday, hitting $14.90. The stock had a trading volume of 1,794,179 shares. Arrowhead Research Corp has a 1-year low of $1.81 and a 1-year high of $27.63. The stock has a 50-day moving average of $11.91 and a 200-day moving average of $14.25. The company’s market cap is $772.9 million.

Arrowhead Research Corp (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.11. On average, analysts predict that Arrowhead Research Corp will post $-0.92 earnings per share for the current fiscal year.

ARWR has been the subject of a number of recent research reports. Analysts at Jefferies Group cut their price target on shares of Arrowhead Research Corp from $30.00 to $29.00 in a research note on Wednesday, May 7th. They now have a “buy” rating on the stock. Separately, analysts at Zacks reiterated an “outperform” rating on shares of Arrowhead Research Corp in a research note on Tuesday, May 6th. They now have a $18.75 price target on the stock. Finally, analysts at Deutsche Bank reiterated a “buy” rating on shares of Arrowhead Research Corp in a research note on Monday, March 24th. Six analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average target price of $22.66.

Arrowhead Research Corporation (NASDAQ:ARWR) is a biopharmaceutical company developing targeted RNAi therapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.